Elevai Labs Inc. (ELAB)
NASDAQ: ELAB · Real-Time Price · USD
0.100
+0.001 (1.01%)
At close: Oct 29, 2024, 4:00 PM
0.0992
-0.0010 (-0.80%)
After-hours: Oct 29, 2024, 7:57 PM EDT
Elevai Labs Revenue
Elevai Labs had revenue of $605.53K in the quarter ending June 30, 2024, with 91.30% growth. This brings the company's revenue in the last twelve months to $2.47M, up 140.04% year-over-year. In the year 2023, Elevai Labs had annual revenue of $1.71M with 123.50% growth.
Revenue (ttm)
$2.47M
Revenue Growth
+140.04%
P/S Ratio
0.60
Revenue / Employee
$137,408
Employees
18
Market Cap
4.94M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.71M | 946.32K | 123.50% |
Dec 31, 2022 | 766.28K | 765.45K | 92,557.44% |
Dec 31, 2021 | 827.00 | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionELAB News
- 7 days ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity - GlobeNewsWire
- 8 days ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity - GlobeNewsWire
- 25 days ago - Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock - GlobeNewsWire
- 26 days ago - REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - GlobeNewsWire
- 26 days ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - GlobeNewsWire
- 27 days ago - Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device - GlobeNewsWire
- 5 weeks ago - Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB) - GlobeNewsWire
- 5 weeks ago - Dow Gains Over 50 Points; Elevai Labs Shares Plummet - Benzinga